

Declarations of Conflicts of Interest

COVID:

Anna Nordvig:

Funded by NIH, grant codes: NIH T32 NS007153-36 and NIH P30 AG066462-01 (Career Development Award). CME Lecture honorarium “Post-COVID-19 Encephalopathy”.

Mike Zandi:

I have received funding support from the NIHR UCL/ULCH BRC and National Brain Appeal charity, and lecturing fees from Eisai and UCB Pharma.

PAIN:

Flavia Mancini:

I have no competing interests. I am funded by the Medical Research Council and, in the past, I received research funding from versus Arthritis.

NEURODEGEN

Bart de Strooper:

Advisor to EISAI, involved previously in collaborations with Janssen Pharmaceutics, Eli-Lilly, Abbvie and others. Scientific founder of K4 therapeutics and Augustine TX.

John Hardy:

No relevant conflicts of interest to declare.

Sarah Tabrizi:

Through the offices of UCL Consultants Ltd, a wholly owned subsidiary of University College London, I have undertaken consultancy services, including advisory boards, for F. Hoffmann-La Roche Ltd and Genentech. I am currently a member of the Invited Lead Member, F. Hoffmann-La Roche's HTT ASO program Steering Committee. All honoraria for these consultancies are paid through UCL Consultants Ltd. I am UK Clinical Principal Investigator for F. Hoffmann-La Roche Ltd's GEN-EXTEND (OLE) and GENERATION-HDI (phase 3) studies for Tominersin (formerly RG6042) and the completed Natural History Study. My work as an investigator on these studies is provided without compensation.

I have previously provided paid consultancy to Ionis Pharmaceuticals on the IONIS-HTTRx programme. All compensation for these services was paid to UCL, my employer. My input to the design and conduct of the Ib/2a trial, my work as a site investigator, and my advice about the OLE, have all been provided without financial compensation.

COGNITIVE:

James Rowe:

No conflicts of interest to declare.

Conflicts of interest – none with the material to be presented. I am Trustee to PSP Association and the Guarantors of Brain, and am Chief Scientific Adviser to Alzheimer Research UK. I am Associate Editor of Brain, and have research grants from AZ-Medimmune, Janssen, Lilly and have been consultant to of received lecture fees from, Ascenuron, UCB, Astex, SVHealth, Biogen and GE Healthcare in the last 3 years, unrelated to the current work.

Fiona Kumfor:

No conflicts of interest to declare.

Masud Husain:

I have had honoraria from Otsuka and Sumitomo Pharma for advisory board contributions.

MUSCLE:

Patrick Chinnery:

No conflicts of interest to declare.

Mike Hanna:

No conflicts of interest to declare.

Francesco Muntoni:

CI of 4 antisense oligonucleotides clinical trials with Sarepta. PI of Sarepta Phase III AAVrh74 microdystrophin. CI of upcoming MDUK/Genethon AAV8 microdystrophin. PI of Ionis/Biogen antisense oligonucleotide nusinersen Phase III study. PI of Avexis AAV9 phase III trials in SMA I. PI of Roche risdiplam jewfish study. PI of AAV8 MTMI gene replacement trial. Member of Pfizer rare disease SAB. Ad-hoc SAB participation for Avexis, Biogen, Dynacure, Dyne Therapeutics, Roche, Sarepta.

NERVE:

David Bennett:

David Bennett has acted as a consultant in the last 2 years for Amgen, Bristows, CODA therapeutic, GlaxoSmithKline, LatigoBio, Lilly, Mundipharma, Orion, Olipass Regeneron and Theranexus on behalf of Oxford University Innovation. David Bennett has an Industrial Partnership grant with Astra Zeneca funded by the BBSRC.

HEADACHE:

Peter Goadsby:

PJG reports, over the last 36 months, grants and personal fees from Amgen and Eli-Lilly and Company, grant from Celgene, and personal fees from Alder Biopharmaceuticals, Aeon Biopharma, Allergan, Biohaven Pharmaceuticals Inc., Clexio, Electrocore LLC, eNeura, Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, MundiPharma, Novartis, Pfizer, Praxis, Sanofi, Santara Therapeutics, Satsuma, Teva Pharmaceuticals, Trigemina Inc., WL Gore, and personal fees for advice through Gerson Lehrman Group, LEK and Guidepoint, fees for educational materials from Massachusetts Medical Society, Medery, Medlink, PrimeEd, UptoDate, WebMD, and publishing royalties from Oxford University Press, and Wolters Kluwer

Patricia Pozo-Roisch:

Scientific Advisory Board of Migraine Research Foundation & Lilly Foundation Spain; Member of the Council of the European Headache Federation; Grants to research group: AGAUR, EraNet NEURON, La Caixa Foundation, Instituto Investigación Carlos III, Migraine Research Foundation; MINECO, Mutual Medica, PERIS and Novartis; Consultancy fees: Allergan, Amgen, Almirall, Biohaven, Chiesi, Eli Lilly, Novartis, Teva Pharmaceuticals; Collaboration in Medical Education projects: Allergan, Almirall, Chiesi, Eli Lilly, Medlink, Medscape, Neurodiem, Novartis, Teva Pharmaceuticals.

Philip Holland:

No relevant conflicts of interest.

NEUROINFLAMM:

Olga Ciccarelli:

Olga Ciccarelli is Deputy Editor of Neurology. No other conflicts of interest.

Jeffrey Bennett:

J.L. Bennett reports payment for consultation from MedImmune/Viela Bio, AbbVie, Alexion, Chugai, Clene Nanomedicine, Genentech, Genzyme, Mitsubishi-Tanabe, Reistone Bio, and Roche; grants and consultation fees from Novartis; and grants from Mallinckrodt and the National Institutes of Health; and has a patent issued for Aquaporumab.

Veronique Miron:

No relevant conflicts of interest to declare.

Ann Yeh:

E.A. Yeh has received research funding from NMSS, CMSC, CIHR, NIH, OIRM, SCN, CBMH Chase and Idea, SickKids Foundation, Rare Diseases Foundation, MS Scientific Foundation (Canada), McLaughlin Centre, Mario Battaglia Foundation. Investigator initiated research funding from Biogen. Scientific advisory: Biogen, Hoffman-LaRoche. Speaker honoraria: MS-ATL; ACRS.

MOVEMENT DISORDERS:

Tony Schapira:

No conflicts of interest to declare.

Tony Lang:

Consultancies for Abbvie, Acorda, AFFiRis, Biogen, Denali, Janssen, Intracellular, Kallyope, Lundbeck, Paladin, Retrophin, Roche, Sun Pharma, Theravance, and Corticobasal Degeneration Solutions. Advisory Board membership for Jazz Pharma, PhotoPharmics, Sunovion. Honoraria from Sun Pharma, AbbVie and Sunovion. Grants from Brain Canada, Canadian Institutes of Health Research, Corticobasal Degeneration Solutions, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, the Ontario Brain Institute, Parkinson Foundation, Parkinson Canada, and W. Garfield Weston Foundation. Royalties from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press.

Anette Schrag:

Consultancies: Abbvie, Biogen, Roche, PD Neurotechnology. Advisory Boards: Biogen, Bial. Grants: European Commission, Parkinson's UK, GE Healthcare, Economic and Social Research Council (ESRC), MDS, National Institute of Health (NIHR), NIHR ULCH BRC

NEUROGENETICS:

Mina Ryten:

No conflicts of interest to declare.

Henry Houlden:

No conflicts of interest to declare.

NEUROINFECTION:

Nick Davies:

No conflicts of interest to declare.

Benedict Michael:

No conflicts of interest to declare.

Tom Solomon:

TS was on the Data Safety Monitoring Committee of the GSK Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children GSK3390107A (ChAd3 EBO-Z) vaccine.

TS chaired the Siemens Healthineers Clinical Advisory Board

TS chaired the Siemens Diagnostics Clinical Advisory Board

TRAUMA:

Vicki Anderson:

No conflicts of interest to declare.

David Loane:

I receive funding from National Institutes of Health, Science Foundation Ireland, and Irish Research Council.

EPILEPSY

Catherine Schevon:

No conflicts of interest to declare.

Matthew Walker:

Inventor on patents: Expression vectors comprising engineered genes (WO2018229254A1),

Combined use of a vector encoding a modified receptor and its exogenous agonist (EP3116508A1)

STROKE:

Keith Muir:

Grant funding: Stroke Association, British Heart Foundation, Innovate UK, Chief Scientist Office

Research Support: Boehringer Ingelheim (drug supply for ATTEST-2)

Advisory Boards: Boehringer Ingelheim, Bayer, Biogen, Daiichi Sankyo, Abbvie, ReNeuron